medigraphic.com
ISSN 1817-5996 (Electronic)

2020, Number S1

<< Back Next >>

Rev Cub de Reu 2020; 22 (S1)

Evidence-based rheumatology

Chacha CFA, Quintana DOS, Paca ATN, Huertas EEM

Language: Spanish
References: 20
Page:
PDF size: 463.02 Kb.


ABSTRACT

The practice of evidence-based medicine is a process that creates the need for clinically important information about diagnosis, prognosis, therapy, and other clinical and health care problems. The objective is to emphasize the current situation of evidence-based rheumatology, highlighting the advances and limitations that the specialty has in this regard. The evidence-based rheumatology provides scientifically based recommendations for clinical practice as a result of the analysis of numerous information generated by reliable sources. In the specialty of rheumatology there is still a group of diseases in which the experience of clinical practice is what guides the work of professionals, since there is no evidence for them supported by extensive research.


REFERENCES

  1. Haynes RB, Sackett DL. Evidence-based medicine. A new approach to teaching the practice of medicine. Evidence-Based Medicine Working Group. JAMA. 1992;268(17):2420-5.

  2. Sackett DL, Rosenberg W, Mc Gray JA, Haynes RB, Richardson WS. Evidence-based medicine: what it is and what it isn't. BMJ. 1996;312:71-2.

  3. Masic I, Miokovic M, Muhamedagic B. Evidence Based Medicine - New Approaches and Challenges. Acta Inform Med. 2008 [Acceso 25/01/2020];16(4):219-25. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789163/

  4. Naylor CD, Naylor CD. Grey zones of clinical practice: some limits to evidence-based medicine. Lancet. 1995;345(8953):840-2.

  5. Pispati PK. Evidence-Based Practice in Rheumatology. Suppliment to Japi. 2006 [Acceso 25/01/2020];54. Disponible en: http://www.japi.org

  6. Pincus T, Yazici H. Evidence-Based Medicine in Rheumatology: ¿How Does It Differ from Other Diseases? In: Understanding Evidence-Based Rheumatology: A Guide to Interpreting Criteria, Drugs, Trials, Registries and Ethics. 2014 Aug. p. 1-12. Doi: https://doi.org/10.1007/978-3-319-08374-2_1

  7. Verhagen AP, de Vet HCW, de Bie RA, Kessels AGH, Boers M, Knipschild PG. Balneotherapy for rheumatoid arthritis and Osteoarthritis (Cochrane Review). In: The Cochrane Library, 2, 2001. Oxford: Update Software; 2001.

  8. Cajigas JC, Ariza R, Espinosa R, Méndez C, Mirassou M, Robles M, et al. Guía de práctica clínica basada en la evidencia para el diagnóstico y tratamiento de la osteoartritis. Med Int Mex. 2011;27(6):552-72.

  9. Eddy D. Evidence-based medicine: A unified approach. Health affairs (Project Hope). 2005;24(1):9-17.

  10. Keeling SO, Alabdurubalnabi Z, Avina-Zubieta A, Barr S, Bergeron L, Bernatsky S, et al. Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. J Rheumatol. 2018 Oct;45(10):1426-39. Doi: https://doi.org/10.3899/jrheum.171459

  11. Lopez-Gonzalez R, Hernandez-Garcia C, Abasolo L, Morado I, Lajas C, Vadillo C, et al. Differences between rheumatology attending physicians and training residents in the management of rheumatoid arthritis in Spain. Scand J Rheumatol. 2008;37:419-26.

  12. Combe B, Logeart I, Belkacemi MC. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort. Ann Rheum Dis. 2014. doi: http://doi.org/10.1136/annrheumdis-2013-204178

  13. Dadoun S, Zeboulon-Ktorza N, Combescure C. Mortality in rheumatoid arthritis over the last fifty years: Systematic review and meta-analysis. Joint Bone Spine. 2013;80:29-33.

  14. Smolen JS, Landewé R, Breedveld FC. EULAR Recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492-509.

  15. Gaujoux-Viala C, Nam J, Ramiro S. Efficacy of conventional synthetic disease modifying anti-rheumatic drugs, glucocorticoids and tofacitinib: A systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:510-5.

  16. Nam JL, Ramiro S, Gaujoux-Viala C. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:516-28.

  17. Ramiro S, Gaujoux-Viala C, Nam JL. Safety of synthetic and biological DMARDs: A systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:529-35.

  18. Felson DT, Smolen JS, Wells G. American College of Rheumatology / European League against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70:404-13.

  19. Singh JA, Furst DE, Bharat A. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying anti-rheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64:625-39.

  20. De Jong PH, Hazes JM, Barendregt PJ. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis. 2013;72:72-8.




2020     |     www.medigraphic.com